![[PDF]](/pb-assets/Icons/adobe-pdf-icon.png){kind=icon}
Abstract
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin administered in counterbalanced sequence with 5 weeks between sessions and a 6-month follow-up. Instructions to participants and staff minimized expectancy effects. Participants, staff, and community observers rated participant moods, attitudes, and behaviors throughout the study. High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the high-dose experience, with >80% endorsing moderately or greater increased well-being/life satisfaction. Community observer ratings showed corresponding changes. Mystical-type psilocybin experience on session day mediated the effect of psilocybin dose on therapeutic outcomes.
Trial Registration
ClinicalTrials.gov identifier: NCT00465595
Keywords Psilocybin, hallucinogen, cancer, anxiety, depression, symptom remission, mystical experience
References
Section:
| Arrieta, O, Angulo, LP, Nunez-Valencia, C. (2013) Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol 20: 1941–1948. Google Scholar, Crossref, Medline, ISI | |
| Barrett, FS, Johnson, MW, Griffiths, RR (2015) Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29: 1182–1190. Google Scholar, SAGE Journals, ISI | |
| Beck, AT, Steer, RA (1987) BDI Beck Depression Inventory Manual. San Antonio, San Diego, Orlando, New York, Chicago, Toronto: The Psychological Corporation Harcourt Brace Jovanovich, Inc. Google Scholar | |
| Benson, PL, Donahue, MJ, Erickson, JA (1993) The Faith Maturity Scale: Conceptualization, measurement, and empirical validation. Res Soc Sci Stud Religion 5: 1–26. Google Scholar | |
| Breitbart, W, Rosenfeld, B, Pessin, H. (2015) Meaning-centered group psychotherapy: An effective intervention for improving psychological well-being in patients with advanced cancer. J Clin Oncol 33: 749–754. Google Scholar, Crossref, Medline, ISI | |
| Carhart-Harris, RL, Bolstridge, M, Rucker, J. (2016) Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry 3: 619–627. Google Scholar, Crossref, Medline, ISI | |
| Carhart-Harris, RL, Leech, R, Hellyer, PJ. (2014) The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Human Neurosci 8(20): 1–22. Google Scholar, Medline, ISI | |
| Carhart-Harris, RL, Erritzoe, D, Williams, T. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109: 2138-2143. Google Scholar, Crossref, Medline, ISI | |
| Cohen, SR, Mount, BM, Strobel, MG. (1995) The McGill Quality of Life Questionnaire: A measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 9: 207–219. Google Scholar, SAGE Journals, ISI | |
| Colleoni, M, Mandala, M, Peruzzotti, G. (2000) Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 356: 1326–1327. Google Scholar, Crossref, Medline, ISI | |
| Derogatis, LR (1992) BSI Brief Symptom Inventory: Administration, Scoring, and Procedures Manual. Minneapolis, MN: National Computer Systems, Inc. Google Scholar | |
| Dittrich, A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2): 80–84. Google Scholar, Crossref, Medline, ISI | |
| Faller, H, Schuler, M, Richard, M. (2013) Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: Systematic review and meta-analysis. J Clin Oncol 31: 782–793. Google Scholar, Crossref, Medline, ISI | |
| Gao, K, Wu, R, Kemp, DE. (2014) Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: A randomized, placebo-controlled trial. J Clin Psychiatry 75: 1062–1068. Google Scholar, Crossref, Medline, ISI | |
| Garcia-Romeu, A, Griffiths, RR, Johnson, MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7: 157–164. Google Scholar, Crossref, Medline | |
| Gasser, P, Holstein, D, Michel, Y. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. Journal Nerv Ment Dis 202: 513–520. Google Scholar, Crossref, Medline, ISI | |
| Grassi, L, Caruso, R, Hammelef, K. (2014) Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: A review. Int Rev Psychiatry 26: 44–62. Google Scholar, Crossref, Medline, ISI | |
| Griffiths, R, Richards, W, Johnson, M. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22: 621–632. Google Scholar, SAGE Journals, ISI | |
| Griffiths, RR, Richards, WA, McCann, U. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187: 268–283. Google Scholar, Crossref, Medline, ISI | |
| Griffiths, RR, Johnson, MW, Richards, WA. (2011) Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 218: 649–665. Google Scholar, Crossref, Medline, ISI | |
| Grob, CS, Danforth, AL, Chopra, GS. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68: 71–78. Google Scholar, Crossref, Medline | |
| Grof, S, Goodman, LE, Richards, WA. (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 8: 129–144. Google Scholar, Crossref, Medline | |
| Halberstadt, AL (2015) Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res 277: 99–120. Google Scholar, Crossref, Medline, ISI | |
| Hayes, AF (2013) Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach. Guildford Press, New York. Google Scholar | |
| Hendricks, PS, Johnson, MW, Griffiths, RR (2015) Psilocybin, psychological distress, and suicidality. J Psychopharmacol 29: 1041–1043. Google Scholar, SAGE Journals, ISI | |
| Holland, JC, Andersen, B, Breitbart, WS. (2013) Distress management. J Natl Comp Cancer Network: JNCCN 11: 190–209. Google Scholar, Crossref, Medline, ISI | |
| Hood, RW, Hill, PC, Spilka, B (2009) The Psychology of Religion: An Empirical Approach. New York: The Guilford Press. Google Scholar | |
| Hood, RW, Ghorbani, N, Watson, PJ. (2001) Dimensions of the mysticism scale: Confirming the three-factor structure in the United States and Iran. J Sci Study Relig 40: 691–705. Google Scholar, Crossref, ISI | |
| ISCDD (2003) GRID-HAMD-17 Structured Interview Guide. San Diego, CA: International Society for CNS Drug Development. Google Scholar | |
| Johnson, M, Richards, W, Griffiths, R (2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol 22: 603–620. Google Scholar, SAGE Journals, ISI | |
| Johnson, MW, Sewell, RA, Griffiths, RR (2012) Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend 123: 132–140. Google Scholar, Crossref, Medline, ISI | |
| Kast, E (1967) Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatr Q 41: 646–657. Google Scholar, Crossref, Medline, ISI | |
| MacLean, KA, Leoutsakos, JM, Johnson, MW. (2012) Factor analysis of the Mystical Experience Questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. J Sci Stud Relig 51: 721–737. Google Scholar, Crossref, Medline, ISI | |
| Matza, LS, Morlock, R, Sexton, C. (2010) Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder. Int J Methods Psychiatr Res 19: 223–232. Google Scholar, Crossref, Medline, ISI | |
| McIntosh, DN (1999) Purpose in Life Test (Crumbaugh & Maholick, 1964). In: Hill, PC, Hood, RW (eds) Measures of Religiosity. Birmingham, AL: Religious Education Press, pp.503–508. Google Scholar | |
| McNair, DM, Lorr, M, Droppleman, LF (1992) Profile of Mood States. San Diego, CA: edITS/Educational and Industrial Testing Service. Google Scholar | |
| Metzner, R, Litwin, G, Weil, G (1965) The relation of expectation and mood to psilocybin reactions: A questionnaire study. Psychedelic Rev 5: 3–39. Google Scholar | |
| Mitchell, AJ, Chan, M, Bhatti, H. (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. Lancet Oncol 12: 160–174. Google Scholar, Crossref, Medline, ISI | |
| Nichols, DE (2016) Psychedelics. Pharmacol Rev 68: 264–355. Google Scholar, Crossref, Medline, ISI | |
| Ostuzzi, G, Matcham, F, Dauchy, S. (2015) Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev 6: CD011006. Google Scholar | |
| Pargament, KI, Koenig, HG, Tarakeshwar, N. (2004) Religious coping methods as predictors of psychological, physical and spiritual outcomes among medically ill elderly patients: A two-year longitudinal study. J Health Psychol 9: 713–730. Google Scholar, SAGE Journals, ISI | |
| Peterman, AH, Fitchett, G, Brady, MJ. (2002) Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy – Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med 24: 49–58. Google Scholar, Crossref, Medline, ISI | |
| Pinquart, M, Duberstein, PR (2010) Depression and cancer mortality: A meta-analysis. Psychol Med 40: 1797–1810. Google Scholar, Crossref, Medline, ISI | |
| Prieto, JM, Blanch, J, Atala, J. (2002) Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol 20: 1907–1917. Google Scholar, Crossref, Medline, ISI | |
| Reker, GT (1992) The Life Attitude Profile-Revised (LAP-R). Peterborough, ON: Student Psychologists Press. Google Scholar | |
| Richards, WA, Rhead, JC, DiLeo, FB, (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9: 1–10. Google Scholar, Crossref | |
| Scheier, MF, Carver, CS (1985) Optimism, coping, and health: assessment and implications of generalized outcome expectancies. Health Psychol 4: 219–247. Google Scholar, Crossref, Medline, ISI | |
| Shear, MK, Vander Bilt, J, Rucci, P. (2001) Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety 13: 166–178. Google Scholar, Crossref, Medline, ISI | |
| Shim, EJ, Park, JH (2012) Suicidality and its associated factors in cancer patients: Results of a multi-center study in Korea. Int J Psychiatry Med 43: 381–403. Google Scholar, SAGE Journals, ISI | |
| Skarstein, J, Aass, N, Fossa, SD. (2000) Anxiety and depression in cancer patients: Relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. J Psychosom Res 49: 27–34. Google Scholar, Crossref, Medline, ISI | |
| Spiegel, D (2015) Existential psychotherapy for patients with advanced cancer: Facing the future and the past. J Clin Oncol 33: 2713–2714. Google Scholar, Crossref, Medline, ISI | |
| Spielberger, CD (1983) Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, Inc. Google Scholar | |
| Strassman, RJ, Qualls, CR, Uhlenhuth, EH. (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51: 98–108. Google Scholar, Crossref, Medline | |
| Studerus, E, Kometer, M, Hasler, F. (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol 25: 1434–1452. Google Scholar, SAGE Journals, ISI | |
| VandeCreek, L (1999) The Death Transcendence Scale (Hood & Morris, 1983). In: Hill, PC, Hood, RW (eds) Measures of Religiosity. Birmingham, AL: Religious Education Press, pp.442–445. Google Scholar | |
| Vollenweider, FX, Kometer, M (2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci 11: 642–651. Google Scholar, Crossref, Medline, ISI | |
| Walker, J, Sawhney, A, Hansen, CH. (2014) Treatment of depression in adults with cancer: A systematic review of randomized controlled trials. Psychol Med 44: 897–907. Google Scholar, Crossref, Medline, ISI | |
| Zigmond, AS, Snaith, RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361–370. Google Scholar, Crossref, Medline, ISI |
